Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
SEARCH · Search NASA
Results for “radiotherapy”
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death
To review the radiobiological mechanisms of stereotactic body radiation therapy stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS).
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
Numerous dose and fractionation schedules have been used to treat medically inoperable stage I non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy. We evaluated published experiences with SBRT to determine local control (LC) rates as a function of SBRT dose.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Spinal Cord Reirradiation:Balancing Benefit Against Risks
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Postoperative Stereotactic Body Radiation Therapy, Then Observe
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Lung Mass With Massive Hemoptysis: Treatment Without Tissue Diagnosis
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy
Spinal cord tolerance data for stereotactic body radiation therapy (SBRT) were extracted from published reports, reviewed, and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (D{sub max}) are estimated to be associated with a 1% to 5% risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions. For reirradiation SBRT delivered in 1 to 5 fractions, reported factors associated with a lower risk of RM include cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 (EQD2{sub 2}) D{sub max} ≤70 Gy; SBRT thecal sac EQD2{sub 2} D{sub max} ≤25 Gy, thecal sac SBRT EQD2{sub 2} D{sub max} to cumulative EQD2{sub 2} D{sub max} ratio ≤0.5, and a minimum time interval to reirradiation of ≥5 months. Larger studies containing complete institutional cohorts with dosimetric data of patients treated with spine SBRT, with and without RM, are required to refine RM risk estimates.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
A Histologic Low-Grade Glioma with 7 Gain, 10 Loss—A Wolf in Sheep’s Clothing
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗
Watch the Mass, Save the Gland (Radiation Therapy Perhaps Later)
No abstract prepared.
62 RADIOLOGY AND NUCLEAR MEDICINE↗